Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of GST-HG131 combined with GST-HG141 in chronic hepatitis B
CTR20262450Phase 2Active
- Sponsor
- Fujian Guangsheng Zhonglin Biotechnology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GST-HG131, narecovir in Chronic Hepatitis B (CHB), sponsored by Fujian Guangsheng Zhonglin Biotechnology. Started Sep 2026; status: active.
02
Drugs
GST-HG131narecovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20262450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262450.